Key facts
- This page summarizes Keith Katkin's Form 4 filing for RIGEL PHARMACEUTICALS INC (RIGL).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 21 May 2021, 20:57.
Keith Katkin - 19 May 2021 Form 4 Insider Report for RIGEL PHARMACEUTICALS INC (RIGL)
- Reporting relationship
- Director
- Issuer ticker
- RIGL
- Reported as of
- 19 May 2021
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 21 May 2021, 20:57:44 UTC
- Next SEC filing
- 02 Feb 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Dolly Vance (Attorney-in-Fact)
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Keith Katkin filed Form 4 for RIGEL PHARMACEUTICALS INC (RIGL) on 21 May 2021.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
RIGL
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +25,000
- Change %
- Price
- $0.000000
- Shares after
- 25,000
- Date
- 19 May 2021
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
RIGL
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +30,000
- Change %
- Price
- $0.000000
- Shares after
- 30,000
- Date
- 19 May 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 30,000
- Exercise price
- $3.64
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the reporting person's continuous service on the Company's Board of Directors.
Footnote F2
The shares vest monthly over one (1) year from the date of grant subject to the reporting person's continuous service on the Company's Board of Directors.